HXHuajun Xu

Huajun Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huajun Xu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Anyuan Zhong

    Department of Respiratory Diseases, The Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou 215004, China

    3 shared publications
  • Minhua Shi

    Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, China

    2 shared publications
  • Xiaolu Xiong

    Department of Endocrinology, Drum Tower Clinical Medical College of Nanjing Medical University, 53 North Zhongshan Road, Nanjing 210008, China

    2 shared publications
  • Chun Wang

    Department of Geriatrics, Drum Tower Clinical Medical College of Nanjing Medical University, 53 North Zhongshan Road, Nanjing 210008, China

    1 shared publication
  • Hongliang Yi

    Department of Otolaryngology Head and Neck Surgery & Center of Sleep Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Yishan Road 600, Shanghai, 200233, China

    1 shared publication
  • Jian Guan

    Department of Otolaryngology-Head and Neck Surgery & Center of Sleep Medicine, Otolaryngology Institute of Shanghai Jiao Tong University, Shanghai Jiao Tong University School of Medicine Affiliated Sixth People’s Hospital, Shanghai, China

    1 shared publication

Latest Publications

  • Meta-analysis of all-cause and cardiovascular mortality in obstructive sleep apnea with or without continuous positive airway pressure treatment

    by Yiqun Fu, Yunyan Xia, Hongliang Yi, Huajun Xu, Jian Guan, Shankai Yin

    Purpose The associations between obstructive sleep apnea (OSA) and all-cause and cardiovascular mortality are well established but are not entirely consistent. To accurately evaluate these associations as well as the therapeutic effects of continuous positive airway pressure (CPAP), we conducted a comprehensive meta-analysis of all eligible cohort studies. Methods Electronic literature databases (i.e., PubMed and Embase) were searched for relevant studies published before January 2016 that evaluated the associations between OSA and all-cause or cardiovascular mortality. Random-effect models were used to calculate the pooled hazard ratio (HR) and corresponding 95 % confidence intervals (CIs) for categorical risk estimates. The therapeutic effects of CPAP treatment for all-cause and cardiovascular mortality in OSA were examined through the meta-analysis. Results The 27 cohort studies included in the meta-analysis included 3,162,083 participants. Compared to the control group, the pooled HR of all-cause mortality was 1.19 (95 % CI, 0.86–1.65) for mild OSA, 1.28 (0.96–1.69) for moderate OSA, and 2.13 (1.68–2.68) for severe OSA. The pooled HR of cardiovascular mortality was 1.24 (0.53–2.55) for mild OSA, 2.05 (0.57–5.47) for moderate OSA, and 2.73 (1.94–3.85) for severe OSA. All-cause mortality (HR 0.66; 0.59–0.73) and cardiovascular mortality (HR 0.37; 0.16–0.54) were significantly lower in CPAP-treated than in untreated patients. There were no differences in cardiovascular mortality in CPAP-treated OSA patients vs. normal control subjects (HR 0.82; 0.52–1.29). Conclusions Greater attention should be paid to severe OSA, as it is an independent predictor for risk for all-cause and cardiovascular mortality. CPAP is an effective treatment that reduces risk of mortality.


  • Open Access

    Association between Self-Reported Habitual Snoring and Diabetes Mellitus: A Systemic Review and Meta-Analysis

    by Xiaolu Xiong, Anyuan Zhong, Huajun Xu, Chun Wang

    Aim. Several studies have reported an association between self-reported habitual snoring and diabetes mellitus (DM); however, the results are inconsistent.Methods. Electronic databases including PubMed and EMBASE were searched. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the association between snoring and DM using a random-effects model. Heterogeneity, subgroup, and sensitivity analyses were also evaluated. Begg’s, Egger’s tests and funnel plots were used to evaluate publication bias.Results. A total of eight studies (six cross sectional and two prospective cohort studies) pooling 101,246 participants were included. Of the six cross sectional studies, the summary OR and 95% CI of DM in individuals that snore compared with nonsnorers were 1.37 (95% CI: 1.20–1.57,p<0.001). There was no heterogeneity across the included studies (I2=2.9%,p=0.408). When stratified by gender, the pooled OR (95% CI) was 1.59 (1.20–2.11) in females (n=12298), and 0.89 (0.65–1.22) in males (n=4276). Of the two prospective studies, the pooled RR was 1.65 (95% CI, 1.30–2.08).Conclusions. Self-reported habitual snoring is statistically associated with DM in females, but not in males. This meta-analysis indicates a need to paying attention to the effect of snoring on the occurrence of DM in females.


  • Open Access

    Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis

    by Anyuan Zhong, Yufei Xing, Xue Pan, Minhua Shi, Huajun Xu

    Background: The association between the expression of programmed cell death-ligand 1 (PD-L1) and survival in patients with non-small-cell lung cancer (NSCLC) is controversial. Thus, we conducted a meta-analysis of all available studies to evaluate the prognostic role of PD-L1 expression in NSCLC. Materials and methods: PubMed, Embase, and Chinese (China National Knowledge Infrastructure and Wanfang) databases were searched to identify all eligible studies evaluating PD-L1 expression and the survival of NSCLC patients. Hazard ratios (HRs) and 95% confidence interval (CI) used to assess overall survival were extracted and pooled. Subgroup, sensitivity, and publication-bias analyses were also performed. Results: Eleven articles reporting 12 studies that included a total of 1,653 patients met the inclusion criteria and were included in the meta-analysis. Higher PD-L1 expression did not correlate with prognosis in terms of overall survival in patients with NSCLC (HR =1.21, 95% CI: 0.85–1.71, P=0.29). However, a subgroup analysis showed a significant association between PD-L1 expression and poor prognosis in Chinese patients with NSCLC (HR =1.55, 95% CI: 1.04–2.29, P=0.03). The sensitivity analysis showed that the pooled results were not affected by the removal of any single study. There was also no significant publication bias. Conclusion: Our meta-analysis indicated no statistically significant difference between PD-L1 expression and prognosis for patients with NSCLC. Additional, high-quality studies with larger sample sizes are needed to determine the prognostic value of PD-L1 expression in NSCLC.


  • Roles of interleukin (IL)-6 gene polymorphisms, serum IL-6 levels, and treatment in obstructive sleep apnea: a meta-analysis

    by Anyuan Zhong, Xiaolu Xiong, Minhua Shi, Huajun Xu

    Inconsistent results regarding the relationship between interleukin (IL)-6 gene polymorphisms, serum IL-6 levels, and the treatment in obstructive sleep apnea (OSA) have been reported. This meta-analysis assessed the associations between IL-6 gene polymorphisms and OSA susceptibility, IL-6 levels in OSA, and CPAP (continuous positive airway pressure) and T&A (tonsillectomy and adenoidectomy) therapy for IL-6 in OSA. Studies regarding IL-6 polymorphisms, serum IL-6 levels, and OSA treatment were identified using PubMed and Embase. The associations between IL-6 gene polymorphisms and OSA risk (estimated by pooling odds ratios (ORs) with 95 % confidence intervals (CIs)) were assessed using an allele model. The pooled standardized mean differences (SMDs) with 95 % CI of IL-6 were estimated using a random-effects model. Meta-regression, sensitivity analysis, and publication bias were also evaluated. In total, 53 studies were included. In adults, a significant association between -174 G/C and OSA susceptibility was observed (OR = 1.46, 95 % CI = 1.14–1.87) and IL-6 levels were higher in OSA compared to controls (SMD = 1.56, 95 % CI = 1.18–1.95); however, no association was observed for the -572 G/C allele (OR = 1.13, 95 % CI = 0.87–1.47) and OSA susceptibility and there was no significant change in IL-6 in pre- and post-CPAP therapy (SMD = −0.24, 95 % CI = −0.73 to 0.26). In children, IL-6 levels were also higher in OSA (SMD = 1.27, 95 % CI = 0.29–2.26) and T&A treatment significantly decreased them (SMD = −0.97, 95 % CI = −1.72 to −0.22). This meta-analysis indicates that the IL-6 gene polymorphism -174 G/C, and not -572 G/C, is associated with adult OSA risk. Although IL-6 levels increased in OSA, CPAP did not significantly suppress them in adults with OSA. In children with OSA, IL-6 levels also increased and T&A therapy significantly decreased them.